September 29, 2020

Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccines

• A phase 1, dose escalation trial of a messenger RNA vaccine against SARS-CoV-2 conducted among adults ages 56-70 (n=20) and ages 71 or older (n=20) reported generating antibody response with mild to moderate adverse events. Serum neutralizing activity was detected in all participants and was similar in magnitude to responses previously reported among participants between the ages of 18 and 55. The authors emphasize the need to include older adults in vaccine trials due to increased risk for severe outcomes from COVID-19 in this age group.

Anderson et al. (Sept 29, 2020). Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2028436